From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elevated glucose blood levels are the key criteria for diagnosing diabetes mellitus (DM). Hyperglycaemia contributes to the pathophysiology associated with DM, including microvascular and possibly macrovascular disease. In spite of a wide range of pharmacological options available to reduce hyperglycaemia in DM, epidemiological studies suggest that glucose levels remain high in a substantial proportion of patients. This supports the need for additional strategies for the treatment of hyperglycaemia. SCOPE: This review focuses on the role of the kidney in glucose reabsorption and explores inhibition of renal glucose reabsorption as a novel approach to treat type 2 DM. A literature search to August 2008 using PubMed was used to compile data for review. Abstracts and presentations from the American Diabetes Association and the European Association for the Study of Diabetes, the American Society of Nephrology, and the International Society of Nephrology Annual Meetings were also searched for relevant studies. FINDINGS: Glucose filtered by the kidney is normally reabsorbed into the proximal renal tubule. Data from animal models suggest that approximately 90% of this reabsorption occurs through the sodium-coupled glucose cotransporter (SGLT) 2, which is a protein expressed almost exclusively in the proximal tubule of the kidney. Inhibition of SGLT2, and thus inhibition of renal glucose reabsorption, has the potential to reduce hyperglycaemia in patients with DM. Patients with familial renal glucosuria, a genetic disorder of SGLT2, do not appear to have adverse clinical consequences related to impaired renal reabsorption of glucose, which suggests that SGLT2 might be both an effective and safe treatment target for hyperglycaemia. In animal models of DM, pharmaceutical inhibition of SGLT2 reduces hyperglycaemia, and may improve insulin resistance. CONCLUSION: Reduction of renal glucose reabsorption is a novel approach to DM treatment that potentially provides improvements in glucose lowering. Various SGLT2 inhibitors are currently in development in human trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Relative or absolute deficiency of insulin and/or glucose promotes preferential metabolism of fats/triglycerides into glycerol and 3 fatty acids (via activation of adipocyte hormone sensitive lipase).”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
In the citing paper
“Increased free fatty acid delivery to the liver (mitochondrial oxidation) generates ketones (e.g., acetone, acetoacetone, and beta-hydroxybutyrate).”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
In the citing paper
“Mild ketosis due to carbohydrate restricted dietary ketosis may have favorable health effects (i.e., decreased hunger; treatment of epilepsy; fatty acids are the main fuel for the heart, which has little glycogen)”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
In the citing paper
“SGLT-2 inhibitors contribute to lower glucose levels, promote negative caloric balance, but do not increase insulin secretion”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
In the citing paper
“Along with fasting, starvation, carbohydrate restricted diets, and poorly controlled type 1 diabetes mellitus, SGLT-2 inhibitors are associated with ketonemia”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 8×
“2009 Informa UK - Curr Med Res Opin 2009; 25(3) The kidney as a target in treating diabetes Bays 675”
BackgroundInfluentialIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Research works printed but not linked: 9
- Kosachunhanun N, 2006, J Med Assoc Thai, 89, S66
- Reaven GM, 2005, Panminerva Med, 47, 201
- Tsujihara K, 1996, I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo), 44, 1174
- Isaji M, 2007, Curr Opin Investig Drugs, 8, 285
- Glombik H, 2004, Chem Abstr, 140
- Washburn W, 2003, Chem Abstr, 138
- Komoroski B, 2009, Clin Pharmacol Ther
- Leslie B, 2008, American Society of Nephrology Renal Week
- Goudswaard AN, 2004, Cochrane Database Syst Rev
Cited by
Ten things to know about ten cardiovascular disease risk factors
Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274
Self-citationSha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S. ‐., Sica, D., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12322 · Cited by 249
Schork, A., Saynisch, J., Vosseler, A., Jaghutriz, B. A., Heyne, N., Peter, A., Häring, H.-U., Stefan, N., Fritsche, A., & Artunc, F. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0852-y · Cited by 227
Devineni, D., Morrow, L., Hompesch, M., Skee, D., Vandebosch, A., Murphy, J., Ways, K., & Schwartz, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01558.x · Cited by 220
Renal glucose reabsorption inhibitors to treat diabetes
Bailey, C. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.011 · Cited by 217
Metadata
- Authors
- Bays, H.
- Affiliations
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Corresponding author
- Bays, Harold
- ORCID
- Bays, Harold
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2009-01-28
- Volume
- 25
- Issue
- 3
- Pages
- 671-681
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2154020052
- Cited by
- 83
- References
- 56
- Citations by year
- 2026: 3 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 4 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 9 · 2016: 5 · 2015: 9 · 2014: 7 · 2013: 5 · 2012: 5
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- SGLT2 inhibitors, type 2 diabetes, renal glucose reabsorption, hyperglycemia, proximal tubule, insulin resistance, glucose-lowering therapy
- MeSH terms
- Diabetes Mellitus, Glucose, Humans, Kidney, Monosaccharide Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. https://app.cochat.ai/papers/10.1185/03007990802710422
- The paper
- Bays, H. (2009). From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Current Medical Research and Opinion. https://doi.org/10.1185/03007990802710422
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.